Palvella Therapeutics, Inc (PVLA NASDAQ) stock market data APIs
$135.5574
-3.7(-2.7%)
as of March 6, 2026
Try our APIs with
free plan!
Palvella Therapeutics, Inc Financial Data Overview
Price chart is built with
Anychart
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Prev. Close
135.5574
Open
131.8578
High
138.4821
Low
130.8375
52 wk Range
18.225-151.18
Market Cap
1 880 M
Shares Outstanding
13 990 K
EPS
-1.03
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Palvella Therapeutics, Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Palvella Therapeutics, Inc data using free add-ons & libraries
Get Palvella Therapeutics, Inc Fundamental Data
Palvella Therapeutics, Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -2.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Palvella Therapeutics, Inc News
New
LGND: 2025 Results & Focus on Qtorin
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2025 results with revenues of $268 million and adjusted core earnings pe...
Palvella Prices $200 Mln Upsized Offering To Advance Late-Stage QTORIN Pipeline
(RTTNews) - Palvella Therapeutics, Inc. (PVLA) has priced an upsized public offering of 1.6 million shares of common stock at $125.00 per share, with expected gross proceeds of $200 million before und...
Palvella Therapeutics Announces Pricing of Upsized Public Offering
WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...
Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy rating on the shares. Phase 3 SELVA data, with the mLM-IGA primary endpoint demonstra...
Get Palvella Therapeutics, Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
